Research Grants
ANNUAL
REPORT 2023
Research Grants
ANNUAL
REPORT 2023
Research Grants
ANNUAL
REPORT 2023
Research Grants
Funds provided by Cancer Australia, the National Health and Medical Research Council, philanthropic funding bodies and pharmaceutical companies in support of ANZUP trials managed by the University of Sydney, are not reported in ANZUP’s financial accounts. Funds provided by Cancer Australia, philanthropic funding bodies and pharmaceutical companies in support of ANZUP trials managed by ANZUP to support trial related costs are reflected in these accounts.
Infrastructure Grants
Previously Cancer Australia’s Infrastructure Grant awarded to ANZUP was managed by the University of Sydney and only those funds transferred to ANZUP in support of specific activities were reported in our financial accounts.
In January 2022 ANZUP was successful in our 2022-2024 Support for Cancer Clinical Trials grant application and was awarded $1,250,000.00 (1 January 2022 to 30 June 2024). ANZUP will administer this During this reporting period ANZUP received AUD$495,000 and is reported in the Annual Accounts.
Other Grants/ Funding during the 2022-23 period are outlined below:
ANZadapt: Phase II randomised controlled trial of patient-specific adaptive versus continuous Abiraterone or eNZalutamide in metastatic castration-resistant prostate cancer. Funding awarded to ANZUP from The Anti-Cancer Foundation (ACF) AUD $982,700 AUD During this reporting period AUD$310,000 was received and is reported in the annual accounts.
BCG+MM: Adding mitomycin to BCG as adjuvant intravesical therapy for high-risk, non–muscle-invasive bladder cancer: a 2-stage, randomised phase 3 trial. Funding awarded from NHMRC AUD$ $1,587,163.80. (2019 – 2023). During this reporting period, AUD$27,000 was transferred to ANZUP and reported in the annual accounts.
CLIMATE: Assessing the Clinical utility of miR-371a-3p as a marker of residual disease in Clinical Stage 1 Testicular Germ Cell Tumour following orchidectomy. Funding awarded from Walter and Eliza Hall Institute of Medical Research $150,000; and ANZUP’s Discretionary Funding AUD$300,000. During this reporting period, AUD$20,000 was received by ANZUP and reported in the annual accounts.
DASL-HiCaP: A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer. Funding awarded Bayer USD$53,173,088. During this period USD$300,000 was transferred to ANZUP and reported in the annual accounts.
ENZAMET: A randomised phase III trial of Enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer. Funding from Astellas AUD$19,962,490 (2014-2022). During this reporting period, AUD$277,737 was transferred to ANZUP and was reported in the annual accounts.
ENZAMET Translational Research Program: During this reporting period no funds were reported in the annual accounts.
ENZA-p: A randomised phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration resistant prostate cancer treated with enzalutamide. Funding from Prostate Cancer Research Alliance: The Australian Government and Movember Foundation Collaboration AUD$4,000,000; Endocyte USD$320,000; St Vincent’s Clinic Foundation AUD$400,000; GenesisCare AUD$300,000; and Roy Morgan Research Ltd AUD$300,000; (2020-2024). During this reporting period, AUD$100,000 and USD$80,000 were transferred to ANZUP and are reported in the annual accounts.
ENZARAD: A randomised phase III trial of Enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised prostate cancer. Funding by Astellas AUD$13,184,412(2014-2022). During this reporting period, no funds were transferred to ANZUP.
EVOLUTION: A randomised phase II trial of Radionuclide 177Lu-PSMA Therapy versus 177Lu-PSMA in Combination with Ipilimumab and Nivolumab for Men with Metastatic Castration Resistant Prostate Cancer (mCRPC). Funding by Prostate Cancer Foundation of Australia AUD$1, 500,000; Bristol Myers Squibb USD$1,296,698, Novartis USD$320,000, (2021-2024). During this reporting period, ANZUP received AUD$600,000 and USD$1,349,116 and is reported in the annual accounts.
GUIDE: A randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care (SOC) docetaxel in metastatic castration-resistant prostate cancer (mCRPC). Funding by Chris O’Brien Lifehouse Foundation Trust is $AUD450,000, and ANZUP’s Discretionary funding is AUD$350,000. During this reporting period, AUD$205,454 was transferred to ANZUP and is reported in the annual accounts.
KEYPAD: A phase II trial using denosumab and pembrolizumab in clear cell renal carcinoma. Funding by Merck Sharpe Dohme and Amgen AUD$2,454,925. During this reporting period, ANZUP received AUD$324,478 and is reported in the annual accounts.
PCR-MIB: Pembrolizumab with Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer. During this reporting period, AUD$245,857 and AUD$464,770 for Translational Research were transferred to ANZUP and both were reported in the annual accounts.
PET-MET: Retrospective analysis of the ENZAMET cohort – Utility of PSMA PET scan quantitation and CT radiomics as prognostic and predictive biomarkers. Funding by Astellas AUD$550,000. During this reporting period, ANZUP received AUD$85,000 and is reported in the annual accounts.
RAMPART: Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART) An international investigator-led phase III multi-arm multi-stage multi-centre randomised controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. Funding by University of College London (UCL) AUD$2,080,000. During this reporting period, ANZUP received AUD$288,624 and is reported in the annual accounts.
TIGER: A Randomised Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilising Paclitaxel plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumours. Funding received from the Movember Foundation AUD$627,987. No funds were received in this reporting period.
UNISON: Phase II sequential cohort trial of Single Agent Nivolumab, then Combination Ipilimumab + Nivolumab in metastatic or unresectable non-clear cell renal cell carcinoma (ANZUP 1602). Bristol Myers Squibb (BMS) provided funding of USD$1,681,822 and product to support the UNISoN trial. During this reporting period, ANZUP received AUD$366,364 and is reported in the annual accounts.
UNICAB: A phase II trial of single agent cabozantinib in patients with locally advanced or metastatic non-clear cell renal cell carcinoma post immunotherapy or who are unsuitable for immunotherapy (ANZUP 1801). No funds were received in this reporting period.